Regulatory Open Forum

 View Only

China announces Updated FAQs for Human Genetic Resource (HGR)

  • 1.  China announces Updated FAQs for Human Genetic Resource (HGR)

    Posted 09-Oct-2023 16:21

    Many foreign device and drug companies now doing clinical trials, R&D, data collection and other related medical activities in China need to follow China's HGR regulations.  HGR regulations outline what foreign companies need to do when applying for, filing and reporting relevant information per the - "Implementation Rules on the Administrative Regulations on Human Generic Resource Administration."  These updated FAQs are to provide companies with clearer answers related to this regulation.

    In many cases, the updated FAQs follow the old FAQs. However, two of the changes among others included in these updated FAQs are listed here. First, with respect to International Collaboration, relevant parties that are not CROs, third-party labs, trial sites, and Sponsors, will now be defined as "other participating parties" if they gain access to HGR information and materials. Second, no longer within the regulatory rules of HGR are biological samples like plasma, serum, etc.  However, if data is produced via trials using some of these materials for mathematical research purposes they may still be regulated as HGR -  if used for international partnerships, etc.  In short, the updated FAQs have tried to reduce the regulatory restrictions on material approvals and the overall supervision of HGR materials.



    ------------------------------
    Ames Gross
    President
    Pacific Bridge Medical
    Bethesda, MD
    www.pacificbridgemedical.com
    contact@pacificbridgemedical.com
    ------------------------------